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Abstract
Background: Multiple myeloma (MM) is characterized by a strong dependence of the tumor cells on their 
microenvironment, which produces growth factors supporting survival and proliferation of myeloma cells (MMC). In 
the past few years, many myeloma growth factors (MGF) have been described in the literature. However, their relative 
importance and the nature of the cells producing MGF remain unidentified for many of them.
Methods: We have analysed the expression of 51 MGF and 36 MGF receptors (MGFR) using Affymetrix microarrays 
throughout normal plasma cell differentiation, in MMC and in cells from the bone marrow (BM) microenvironment 
(CD14, CD3, polymorphonuclear neutrophils, stromal cells and osteoclasts).
Results: 4/51 MGF and 9/36 MGF-receptors genes were significantly overexpressed in plasmablasts (PPC) and BM 
plasma cell (BMPC) compared to B cells whereas 11 MGF and 11 MGFR genes were overexpressed in BMPC compared 
to PPC. 3 MGF genes (AREG, NRG3, Wnt5A) and none of the receptors were significantly overexpressed in MMC versus 
BMPC. Furthermore, 3/51 MGF genes were overexpressed in MMC compared to the the BM microenvironment 
whereas 22/51 MGF genes were overexpressed in one environment subpopulation compared to MMC.
Conclusions: Two major messages arise from this analysis 1) The majority of MGF genes is expressed by the bone 
marrow environment. 2) Several MGF and their receptors are overexpressed throughout normal plasma cell 
differentiation. This study provides an extensive and comparative analysis of MGF expression in plasma cell 
differentiation and in MM and gives new insights in the understanding of intercellular communication signals in MM.
Background
Multiple myeloma (MM) is a B cell neoplasia that affects
15 000 new patients per year in Europe and 15 000 in the
United States. It is still an incurable disease with an aver-
age 5-year survival after high dose chemotherapy and
autologous stem cells transplantation [1]. MM is charac-
terized by the accumulation of a clone of malignant
plasma cells in the bone marrow (BM). Hallmarks of MM
are the presence of genetic abnormalities [2] and the
dependence of tumor cells on their environment through
cell communication signals [3]. Since the identification of
IL-6 [4-6] and IGF-1 [7] as major myeloma growth factor
(MGF) in 1988 and 1996, respectively, the identification
of new autocrine and/or paracrine MGF has been con-
stantly increasing, making it difficult to understand inter-
cellular communication signals in MM (see [3,8] for
review and Table A1A). This is however a major question,
in particular with the aim to design novel targeted thera-
pies for MM.
In this study, we have used U133P 2.0 Affymetrix
microarrays to analyse the expression of a large panel of
MGF in BM aspirates from MM patients, in purified cell
subpopulations present in the BM of those patients, i.e
CD138+ multiple myeloma cells (MMC), CD14+ mono-
cytes, CD15+ polymorphonuclear neutrophils (PMN)
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Table 1: List of growth factors investigated in the study.
A. Growth factors that have been reported to be involved in myeloma biology.
Growth factor probe set References (*)
- Insulin-like growth factor-1 (IGF-1) 209541_at [7,35-39]
- Hepatocyte growth factor (HGF) 210997_at [41-46]
- Macrophage inflammatory protein1 α 
(MIP1α/CCL3)
205114_s_at [53-56]
- Growth/differentiation factor 15 (GDF15) 221577_x_at [24]
- pleiotrophin (PTN) 209466_x_at [57,58]
- Brain derived neurotrophic factor (BDNF) 206382_s_at [59]
IL-6 family cytokines
- Interleukin 6 (IL-6) 205207_at [4,5,19,33-35,60-68]
- Ciliary neurotrophic factor (CNTF) NA [69]
- oncostatin M (OSM) 230170_at " "
- Leukemia inhibitory factor (LIF) 205266_at " "
- Interleukin 11 (IL-11) NA " "
- cardiotrophin-like cytokine factor1 
(CLCF1)
219500_at [70]
Other interleukins
- interleukin 1β (IL-1β) 39402_at [18]
- interleukin 10 (IL-10) 207433_at [71,72]
- interleukin 15 (IL-15) 205992_s_at [73]
- interleukin 21 (IL-21) NA [74]
TNF family members
- tumor necrosis factor α (TNF-α) 207113_s_at [75-78]
- B cell activating factor (BAFF/TNFSF13B) 223501_at [9,79-82]
- A proliferation inducing ligand (APRIL/
TNFSF13)
210314_x_at " "
EGF family members (**)
- amphiregulin (AREG) 205239_at [17,28]
- heparin-binding EGF-like growth factor 
(HB-EGF)
203821_at [17,83,84]
- neuregulin 1 (NRG1) 208241_at [17]
- neuregulin 2 (NRG2) 206879_s_at " "
- neuregulin 3 (NRG3) 229233_at " "
- neuregulin 4 (NRG4) 242426_at " "Mahtouk et al. BMC Cancer 2010, 10:198
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FGF family members
- fibroblast growth factor 2/basis FGF 
(FGF2/bFGF)
204422_s_at [32,51]
Wnt family members [47-49]
- Wnt5A 205990_s_at
- Wnt10B NA
- Wnt16 224022_x_at
Jagged family [85-88]
- Jagged 1 (JAG1) 209099_x_at
- Jagged 2 (JAG2) 32137_at
VEGF family
- Vascular endothelial growth factor A 
(VEGFA)
212171_x_at [31,89-92]
B. Members of the VEGF, FGF, and Wnt family.
Growth factor probe set
VEGF family (5 members)
- VEGFA* 212171_x_at
- VEGFB 203683_s_at
- VEGFC 209946_at
- VEGFD/FIGF NA
FGF family members (22 members)
- FGF1 1552721_a_at
- FGF2* 204422_s_at
- FGF3 214571_at
- FGF4 206783_at
- FGF5 210311_at
- FGF6 208417_at
- FGF7 230918_at
- FGF8 NA
- FGF9 206404_at
- FGF10 NA
- FGF11 227271_at
- FGF12 1562794_at
- FGF13 205110_s_at
- FGF14 231523_at
- FGF16 NA
- FGF17 NA
- FGF18 231382_at
Table 1: List of growth factors investigated in the study. (Continued)Mahtouk et al. BMC Cancer 2010, 10:198
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and CD3+ T cells, as well as in in vitro-generated bone
marrow stromal cells (BMSC) and osteoclasts. We pro-
vide for the first time a comprehensive overview of
growth factor expression in the different BM cell popula-
tions of patients with MM.
Methods
Patients and cell samples
Samples were obtained in agreement to the French and
German ethical laws. MMC were purified from the BM of
131 patients with newly-diagnosed MM (median age, 59
years) after written informed consent was given. The
study has been approved by the ethic boards of Heidel-
berg University and Montpellier University hospitals.
According to Durie-Salmon classification, 14 patients
were of stage IA, 24 of stage IIA, 76 of stage IIIA, 14 of
stage IIIB, one had a plasma cell leukaemia and 2 were of
undetermined stage. Human normal bone marrow sam-
ples were obtained from filtration residues of the bone
marrow harvested from healthy donors for stem cell
allograft after agreement of the Center of Biological
Resources of the Montpellier University Hospital. Buffy
coats of peripheral blood cells were purchased from the
French Blood Center according to a written approved
convention between French Blood Center and Montpel-
lier University Hospital. Normal BM plasma cell (BMPC)
and primary MMC were purified using using autoMACS
with anti-CD138 MACS microbeads (Miltenyi-Biotec,
Paris, France) as previously described [9]. For the isola-
t ion o f  periphe ra l bl ood m e m ory B c e lls ( M B) ,  mo no-
cytes, NK and T cells were first removed using anti-
CD14, anti-CD16 and anti-CD3 magnetic beads (Dynal),
- FGF19# NA
- FGF20 NA
- FGF21 NA
- FGF22 NA
- FGF23 NA
Wnt family members (19 members)
- Wnt1 NA
- Wnt2 205648_at
- Wnt2B NA
- Wnt3 229103_at
- Wnt3A NAΨ
- Wnt4 208606_s_at
- Wnt5A* 205990_s_at
- Wnt5B 221029_s_at
- Wnt6 71933_at
- Wnt7A 210248_at
- Wnt7B NA
- Wnt8A 224259_at
- Wnt8B NA
- Wnt9A NA
- Wnt9B NA
- Wnt10A 223709_s_at
- Wnt10B* NA
- Wnt11 206737_at
- Wnt16* 224022_x_at
A. (*) The list of references is not exhaustive, and includes the original or major studies. (**) Among all ten EGF-family members, only those 
having a heparin-binding domain are listed here. Indeed, only EGF-ligands that bind the HSPG syndecan-1 present on MMC can stimulate 
myeloma cell growth [17]. Probe sets noted "NA" were considered to be "non-informative" (see additional file 1).
B. * Indicates that the growth factor has already been reported to be involved in myeloma biology (they are also listed in table 1A). # FGF19 
is the human orthologue of FGF15 and was cloned by homology to mouse FGF15. Ψ Indicates that no probe set was found for this gene. Probe 
sets noted "NA" were considered to be "non-informative" (see additional file 1).
Table 1: List of growth factors investigated in the study. (Continued)Mahtouk et al. BMC Cancer 2010, 10:198
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and MB cells were then positively selected using anti-
CD27 MACS microbeads (Miltenyi Biotec). Polyclonal
plasmablasts (PPC) were generated from purified periph-
eral blood CD19+ B cells in vitro, as described [10,11].
Whole BM samples (WBM) were obtained from 75 of the
131 patients with MM whose MMC were purified.
According to the Durie-Salmon classification, 12 patients
were in stage IA, 15 in stage IIA, 45 in stage IIIA, three in
stage IIIB. In addition, BM T lymphocytes (CD3+),
monocytes (CD14+) and polymorphonuclear neutrophils
(PMN, CD15+) were simultaneously purified from the
BM of five of those 75 patients, as described previously
[9]. Stromal cells (BMSC, n = 5) and osteoclasts (n = 7),
which cannot be harvested in BM aspirates, were gener-
ated in vitro from the BM of MM patients, as described
[9].
Preparation of complementary RNA (cRNA), microarray 
hybridization and gene expression profiling analysis
Microarray experiments were performed at the Institute
o f  R e s e a r c h  i n  B i o t h e r a p y  http://irb.chu-montpellier.fr/
en/laboratories_microarray.html in the Montpellier Uni-
versity Hospital. RNA was extracted with the RNeasy Kit
(Qiagen) or the SV-total RNA extraction kit (Promega)
and Trizol (Invitrogen), in accordance with the manufac-
turer's instructions. Biotinylated complementary RNA
(cRNA) was amplified with a double in-vitro transcrip-
tion, according to the Affymetrix small sample labelling
protocol vII (Affymetrix). The biotinylated cRNA was
fragmented and hybridized to the HG-U133 Plus 2.0
GeneChip oligonucleotide arrays according to manufac-
turer's instructions (Affymetrix). Fluorescence intensities
were quantified and analyzed using the GCOS software
(Affymetrix). Arrays were scaled to an average intensity
of 100. A threshold of 1 was assigned to values under 1.
Gene expression data were analysed with our bioinfor-
matics platforms: RAGE, http://rage.montp.inserm.fr[12]
and "Amazonia!", http://amazonia.montp.inserm.fr[13].
All microarray data presented in this paper have been
deposited in the ArrayExpress public database, under
accession numbers E-MEXP-2360 for BMPC [11] and E-
TABM-937 for B cells, PPC, MMC and environment pop-
ulation samples. We also used Affymetrix data of 22 nor-
mal BMPC samples and a cohort of 345 purified MMC
from previously-untreated patients from the Arkansas
Research Group (Little Rock) [14,15]. These data are pub-
licly available in the NIH Gene Expression Omnibus
(GEO) http://www.ncbi.nlm.nih.gov/geo/ under acces-
sion number GSE2658 for MMC samples and GSE5900
for 22 normal BMPC.
Statistical analysis
For supervised analyses, differentially expressed genes
were identified by a student t-test, and p-values were
adjusted for multiple comparisons using the Benjamini
and Hochberg correction. The threshold for significance
was set to a p value ≤ 0.05. Among those genes, those
with a fold change ≥ 2 were retained. Among the genes
found to be statistically overexpressed with a fold change
≥ 2 in a given population, those with 100% absent call in
this population were considered not to be biologically rel-
evant and were removed. The call ("present" or "absent")
is determined by Affymetrix GCOS-software and indi-
cates whether a gene is reliably expressed or not. Regard-
ing analysis on the different environment populations,
whole bone marrow samples (WBM) were not included
for supervised analysis. They include both MMC and
environment cells and the expression of a given gene
could be the reflection of its expression in MMC or in the
environment or both.
Results
Affymetrix microarrays to investigate Myeloma Growth 
Factor (MGF) expression in BM subpopulations
Based on the literature data, we have listed 32 growth fac-
tors that have already been described as growth factors
for MMC (Table A1A). As VEGFs, Wnts and FGFs are
members of families with strong homologies, we
extended the study to all members of those families, even
if only some of them have already been shown to play a
role in MM (Table B1B). Gene expression of 24/32 known
MGF, 3/4 VEGFs, 13/22 FGFs and 11/19 Wnts could be
interrogated with Affymetrix U133 Plus 2.0 arrays
(Tables A1A and B1B). Other genes could not be studied
due to a lack of probe set (one gene: Wnt3A) or to a "non-
informative" probe set, i.e. with a low signal and an absent
call in ≥ 95% of the samples (20 genes, see additional file
1). Thus 51 growth factors could be interrogated by 147
probe sets. When several probe sets were available for a
given gene, the probe set with the highest percentage of
"present call" among all samples or the one with the high-
est variance in case of 100% presence was selected. Probe
sets are listed in Tables A1A and B1B.
The majority of MGF are overexpressed in the tumor 
environment compared to MMC
In order to identify which MGF are expressed by each cell
component of the BM, we compared the expression of the
51 MGF genes among all BM subpopulations. 3/51 MGF
genes - FGF7, NRG3, Wnt10A - were statistically signifi-
cantly overexpressed in purified myeloma cells (MMC, n
= 131) compared to each other BM population: T cells
(CD3, n = 5), monocytes (CD14, n = 5), CD15+ polymor-
phonuclear neutrophils (PMN, n = 5), bone marrow
stromal cells (BMSC, n = 5), and osteoclasts (n = 7) (p ≤
.05, fold-change ≥ 2). They were defined as "myeloma
MGF" (Figure 1 and additional file 2, table S-I). 22/51
genes were overexpressed in cells from the environmentMahtouk et al. BMC Cancer 2010, 10:198
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Page 6 of 18
compared MMC (p ≤ .05, fold-change ≥ 2). 14 out of
those 22 MGF genes were overexpressed in cells of the
putative tumor niche, i.e BMSC (11 genes) and osteo-
clasts (3 genes), compared to MMC and other BM sub-
populations (CD3, CD14 and PMN). They were defined
as "myeloma niche MGF" (Figure 1 and additional file 2,
table S-II). 8/22 genes were overexpressed in at least one
BM subpopulation (CD3, CD14 and/or PMN) compared
to MMC, BMSC and osteoclasts (p ≤ .05, fold-change ≥
2). They were defined as "environment MGF" (Figure 1
and additional file 2, table S-III). 17/51 genes were not
classified by the supervised analysis. For the majority of
them (12 genes), the reason is that they were highly
expressed both in MMC and in at least one environment
population (Figure 1 and additional file 2, table S-IV).
The five remaining genes (NRG2, Wnt4, Wnt11, Wnt16
and FGF18) were considered as a "myeloma MGF"
although they were not statistically significantly overex-
pressed in MMC compared to environment cell popula-
tions. Indeed, they displayed a present call in some of the
MMC samples whereas they were absent in all other BM
populations (see additional file 2, table S-I). Finally, 9/51
MGF were not/weakly expressed, neither in MMC nor in
the environment. They had less that 5% of presence in
MMC samples and BM subpopulations and they were not
expressed in BMSC and osteoclasts (data not shown).
Those genes include 5 members of the FGF family
(FGF3,4,6,11,14), 3 members of the Wnt family
(Wnt2A,7A,8A) and NRG4. This lack of expression could
not be attributed to a lack of detection by a non-func-
tional Affymetrix probe set, as expression of these genes
could be detected using Affymetrix microarrays in vari-
ous normal tissues (data not shown, see additional file 1).
Altogether, those data indicate that the majority of MGF
are overexpressed by the environment compared to
MMC, and suggest that BMSC are the main source of
MGF.
MGF genes overexpressed in MMC compared to the 
environment
The 3 "myeloma MGF" as well as FGF18, NRG2, Wnt4,
Wnt11 and Wnt16 (100% absent call in all environment
populations) are represented in Figure 2. For clarity of the
presentation, only 44/131 MMC samples as well as 44
whole BM samples (including MMC and cells of the envi-
ronment; WBM), both obtained from the same patients,
are depicted here. "Myeloma MGF" include 2 members of
the EGF family (NRG2 and NRG3), 2 members of the
FGF family (FGF7 and FGF18) and 4 members of the Wnt
family (Wnt4, Wnt10A, Wnt11 and Wnt16). Except for
FGF7, those 8 MGF displayed 100% absent call in all
other BM cell populations (table S-I). Hence, the expres-
sion detected in the WBM samples is due to the MMC
(Figure 2, right panel) and those factors are exclusively
autocrine for the MMC. Three of these 8 genes - FGF7,
Wnt4 and Wnt10A - were also expressed in normal
plasma cells (Figure 2).
MGF genes overexpressed in cells of a putative myeloma 
niche, i.e BMSC and osteoclasts, compared to MMC and 
other BM subpopulations
The 14 "myeloma niche" MGF are represented in Figure
3. 11/14 genes were overexpressed in BMSC compared to
all other BM populations (p ≤ .05, fold-change ≥ 2):
BNDF, 3 members of the FGF family (FGF1, FGF2,
FGF5), GDF15, IL-6, JAG1, LIF, VEGFC and 2 members
of the Wnt family (Wnt3 and Wnt5B) (Figure 3A). 3/14
genes were overexpressed in osteoclasts compared to all
other BM populations (p ≤ .05, fold-change ≥ 2): IGF1,
IL10 and April (Figure 3B). IGF-1 and IL-6 have been
extensively described as paracrine myeloma growth fac-
tors [5,6]. Accordingly, they belong to the "myeloma
niche" category. Interestingly, IL-6 and IGF-1 were also
expressed by the MMC themselves, in 60% and 100% of
the patients, respectively (% of present call, table S-II),
but at a lower level than in BMSC for IL-6 (median IL-6
expression in MMC = 55, versus 1867 in BMSC, table S-
II) and in osteoclasts for IGF-1 (median IGF-1 expression
in MMC = 424, versus 1104 in osteoclasts, table S-II).
MGF genes overexpressed in cell subpopulations of the 
environment compared to MMC, BMSC and osteoclasts
The 8 "environment" MGF are represented in figure 4A
and listed in additional file 2, Table S-III. CD14-positive
monocytes overexpressed 6/8 "environment" MGF (p ≤
.05, fold-change ≥ 2): 2 TNF-superfamilly members
(TNFSF13B/BAFF and TNF-α), OSM, IL-1β, IL15 and
HB-EGF. CD15-positive PMN also overexpressed BAFF
and OSM, as well as FGF13, compared to MMC, BMSC
and osteoclasts. Thus, monocytes and PMN may be an
important source of growth factors for the tumor, espe-
cially because PMN represent around 50% of the cells in
the BM [16]. CD3+ T cells overexpressed FGF9 (Table S-
III).
MGF genes expressed both by MMC and the environment
12/51 genes were not classified by the supervised analysis
(T able S-IV). For seven of them, the reason is that they
were highly expressed both in MMC and in at least one
environment cell population: AREG, Wnt5A, CCL3,
CLCF1, VEGF, FGF12 and HGF (Figure 4B and table S-
IV). AREG was expressed in MMC and WBM samples, as
well as in CD3, CD14 and PMN subpopulations, but it
was weakly or not expressed by BMSC and osteoclasts. In
contrast, Wnt5A was not expressed in WBM samples and
in the subpopulations, but it was expressed in osteoclasts
and BMSC. It should be noted that HGF expression in
MMC (median = 218) was not significantly higher thatMahtouk et al. BMC Cancer 2010, 10:198
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that in BMSC (median = 194, p = 0.4), CD14 (median =
99, p = 0.1) and PMN (median = 102, p = 0.1). However,
HGF expression in MMC among 131 patients was very
heterogeneous and it could be very high in some patients'
MMC (range 1 to 5378). Other 5 genes (PTN, NRG1,
JAG2, VEGFB and Wnt6) were also expressed in MMC
and environment cells, but without any change in signal
between present or absent call (data not shown). This
may suggest that those probe sets poorly work. It may
also be that the expression level is at the limit of sensitiv-
ity and thus can hardly be detected by Affymetrix probe
sets. This is likely the case for NRG1 whose gene expres-
sion measured by real-time PCR has been already docu-
mented in MM [17].
Growth factor receptor expression in MMC
Because the aim of this study was to describe the expres-
sion of growth factors that sustain myeloma cell growth
through paracrine or autocrine stimulation, we focused
on the analysis of receptor expression in MMC only.
However, we cannot exclude that MGF receptor expres-
sion by cells from the environment (data not shown)
could indirectly influence myeloma cell growth as well.
Among 48 MGF receptors that are listed in Table 2, 36
could be interrogated with Affymetrix microarrays. Half
of the MGF receptor genes (18/36) were expressed in
more than 50% of the MMC samples (present call, Table
2). Among them, 4 MGF receptor genes were expressed
in 100% of the patients (IL-6ST, IL-10 RB, BCMA or
Figure 1 The majority of MGF is expressed by the BM environment of patients with MM. 42/51 MGF genes that are expressed in MMC and/or 
in the environment are represented in a Venn diagram according to their overexpression in each BM population compared to the others (p ≤ .05, fold-
change ≥ 2). *Indicates that those 5 genes were expressed in MMC and environment cells, but without any change in signal between present or ab-
sent call (data not shown). This suggests that either those probe sets poorly work or their expression level is at the limit of sensitivity and thus can 
hardly be detected by Affymetrix probe sets. # Those genes were not statistically significantly overexpressed in MMC, but they displayed an absent call 
in all environment population (see additional file 2, table S-I) and they were thus defined as "myeloma MGF".
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Notch 2), 1 MGF receptor gene was expressed in 99% of
them (IL-6R) and 5 MGF receptor genes were expressed
in more than 90% of the patients (IL-10RA, TACI and Frz
receptors 4,7 and 9). This indicates that the vast majority
of the patients, if not all, have receptors for IL-6, IL-10,
Baff/April and Wnt. 14/36 MGF receptor genes were
expressed in 10-50% of the patients and 4/36 of them
were expressed in less than 10% of the patients (table 2).
CLCF1R was absent is 100% of the MMC samples and
IL1R in 99% of them (in agreement with previous data
[18]), suggesting that their respective ligands produced by
the environment (see figure 4) have no biological rele-
vance to MMC.
Expression of MGF and MGF receptors throughout normal 
PC differentiation and in MMC
In order to investigate the expression of MGF and MGF
receptors throughout normal PC differentiation and in
the generation of malignant plasma cells, we compared
the expression of the 51 MGF and 36 MGF receptor genes
in memory B cells (MB, n = 6), in in vitro-generated plas-
mablasts (PPC, n = 7) in purified bone marrow plasma
Figure 2 Gene expression of "myeloma MGF" in bone marrow subpopulations. (A) Overexpressed genes in MMC versus CD14, PMN, CD3, BMSCs 
and osteoclasts (p ≤ .05, fold-change ≥ 2). (B) MMC genes that were not statistically significantly overexpressed in MMC but displayed an absent call 
in all environment population (see additional file 2, table S-I). Histograms show the gene signal intensity on the Y axis as arbitrary units determined by 
the Affymetrix software. Each histogram features the same samples: 6 MB, 7 PPC, 7 BMPC, 44 MMC, 44 WBM, 5 CD3+/CD14+/PMN samples from newly 
diagnosed myeloma patients, 5 BMSC and 7 osteoclast samples generated in vitro. Expression data of 131 MMC samples and 75 WBM samples are 
presented in additional file 2. For clarity of the presentation, only 44/131 MMC and 44/75 WBM, both obtained from the same patients, are depicted 
here. White bars indicates that the gene displays an "absent" detection call. Abbreviations: MB, memory B cells; PPC, plasmablasts; BMPC, bone marrow 
plasma cells; MMC, myeloma cells, WBM, whole BM; CD3, T cells; CD14, monocytes; PMN, polymorphonuclear neutrophils; BMSC, stromal cells; OC, 
osteoclasts.
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cells (BMPC, n = 7), and MMC (n = 131). Data are shown
in additional file 3, figures S-I and S-II and additional file
2, tables S-V and S-VI. The expression of 8 MGF and 10
MGF receptor genes was statistically significantly differ-
ent between B cells and "PPC+BMPC" (p ≤ .05, fold-
change ≥ 2). 4 MGF genes (OSM, Wnt6, Wnt16 and
F G F 9 )  w e r e  u p - r e g u l a t e d  i n  B  c e l l s ,  w h e r e a s  o t h e r s  4
(FGF7, CCL3, Wnt5B and IGF1) were up-regulated in
"PPC+BMPC". 1 MGF receptor gene (IL10RA) was up-
regulated in B cells, whereas other 9 genes were up-regu-
Figure 3 Gene expression of "myeloma niche MGF" in bone marrow subpopulations. Genes overexpressed in BMSCs (A) and in osteoclasts (B) 
versus CD14, PMN, CD3 and MMC (p ≤ .05, fold-change ≥ 2). See also legend of Figure 2.
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lated in "PPC+BMPC" (p ≤ .05, fold-change ≥ 2): 3 FRZ-
family members (FRZ1,3,6), the 2 members of the IL6R
complex (IL-6R and IL-6ST), IL15RA, Met, TNFRSF17
and IL21R.
Interestingly, the expression of 12 MGF and 12 recep-
tors was significantly different between PPC and BMPC,
11/12 MGF and 11/12 MGF receptor genes being up-reg-
ulated in BMPC compared to PPC (p ≤ .05, fold-change ≥
2; figures S-I and S-II). Those 11 MGF genes include 2
Wnt-family members (Wnt5A, Wnt10A), 2 VEGF-family
members (VEGFB and C), 1 FGF-family member (FGF2),
1 EGF-family members (AREG), 2 TNF-family members
(Baff, April), PTN, CCL3 and JAG1. MGF receptor genes
comprise 5 members of the FRZ family (FRZ1,2,6,7,8),
IL6ST, NTRK2, Notch4, TNFRSF1A, CCR1 and LIFR.
IL21R was upregulated in PPC. These data emphasize an
increased expression of genes encoding for MGF and
their receptors throughout plasma cell differentiation, in
particular during late plasma cell stage, i.e in BMPC. It is
noteworthy that FRZ receptor expression is a hallmark of
PC differentiation.
We then compared the expression of the 51 MGF and
36 receptor genes in MMC and in BMPC. Only 3 MGF
and 1 MGF receptor gene (FZD2) were significantly dif-
ferentially expressed between MMC and BMPC (p ≤ .05,
fold-change ≥ 2). FZD2 was overexpressed in BMPC,
whereas all three MGF genes were overexpressed in
MMC: AREG, NRG3 and Wnt5A. AREG and WNT5A
were also upregulated in BMPC compared to PPC. In
contrast, NRG3 was not expressed in any normal popula-
tion (100% absent call) but it was expressed in 73% of the
p a t i e n t s ' s a m p l e s  w i t h  a  v e r y  s t r o n g  s i g n a l  i n  s o m e  o f
them (see Figure 2). Those 3 MGF genes were also found
to be overexpressed in MMC versus BMPC (p ≤ .05, fold-
change ≥ 2) in an independent publicly available data set
of 22 BMPC and 345 MMC patients' samples from the
Arkansas Research Group (Little Rock, additional file 2,
table SVII-A). Of note, 10/51 MGF and 5/36 receptor
genes were "absent" in all BMPC samples (data not
shown) whereas they were expressed in more than 10%
(present call) of the MMC samples (see additional file 2).
Hence, they may also be considered as being aberrantly
expressed in MMC compared to normal BMPC although
they are not statistically significantly overexpressed in
MMC. Those MGF genes include HGF, 2 EGF-family
members (HB-EGF and NRG2), 3 Wnt-family members
(Wnt5B, Wnt11, Wnt16), 2 FGF-family members (FGF9,
FGF18), BDNF and TNF-α (data not shown). MGF recep-
tor genes include FGFR3, IL11R, IGF1R, FRZ4 and LRP6.
Additional normal samples would be required to con-
clude about their relative expression in normal versus
tumor cells. Among them, one MGF (HGF) and one MGF
receptor (IL-11R) genes were statistically significantly
overexpressed in MMC versus BMPC in the publicly
available data set of 22 BMPC and 345 MMC patients'
samples (p ≤ .05, fold-change ≥ 2; additional file 2, table
S-VII).
Discussion
Two major messages arise from this study. 1) The major-
ity of MGF genes is expressed by the bone marrow envi-
ronment. 2) Several MGF and their receptors are
overexpressed throughout normal plasma cell differentia-
tion.
22 out of the 51 MGF genes that could be interrogated
by Affymetrix were significantly overexpressed by at least
one BM environment population compared to others and
to MMC, whereas only 3 of them were significantly over-
expressed in MMC compared to the environment. These
data emphasize the importance of the tumor microenvi-
ronment in MM pathogenesis. Purified primary MMC
rapidly undergo apoptosis as soon as they are purified,
suggesting that MGF produced by MMC themselves are
not sufficient to maintain their survival [19]. The envi-
ronment niche for MMC is not elucidated presently. It
may resemble the normal plasma cell niche which com-
prises SDF-1-producing stromal cells and that is shared
with hematopoietic stem cells and pre pro B cells [20].
Several studies have confirmed the importance of the
endosteal cells, in particular BMSC (differentiated or not
into osteoblasts) and osteoclasts to support myeloma cell
proliferation and survival [21,22]. Other cells of the BM
environment (CD14, CD3, PMN) and minor populations
like plasmacytoid dendritic cells [23] could be important
as well. In this study, we show that BMSC and osteoclasts
are the main source of MGF. They highly express 11/21
and 3/21 "environment" MGF genes, respectively, in par-
ticular MGF that have been reproducibly identified in
several studies: IGF-1, IL-6, APRIL, IL-10 [3]. In addition,
these two cell types produce complementary sets of MGF,
insuring that the endosteal niche could provide an opti-
mal cocktail of growth factors for MMC survival. A point
to emphasize is that MMC may progressively select a
tumor-promoting environment. We have shown that
B M S C  f r o m  M M  p a t i e n t s  ( M M - B M S C )  s u p p o r t  t h e
growth of a stroma-dependent myeloma cell line better
than normal BMSC and show a reduced matrix minerali-
sation capability [24]. Furthermore, BMSC from MM
patients and from normal donors have a distinctive gene
expression profile on microarrays analysis [24]. The fact
that MM-BMSC have a specific gene signature although
they have been cultured in vitro for several days in the
absence of malignant plasma cells (cells are harvested
after 41 days of culture for microarrays analysis [24]) sug-
gest that cells harvested from the bone marrow microen-
vironment of myeloma patients keep their specific
features even after in vitro culture. The second interest-
ing finding is that MGF and MGF receptor gene expres-Mahtouk et al. BMC Cancer 2010, 10:198
http://www.biomedcentral.com/1471-2407/10/198
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Figure 4 Gene expression of "environment MGF", and MGF expressed both in MMC and in the environment. (A) Genes overexpressed in at 
least one of the population CD14, PMN, CD3 versus MMC, BMSCs and Ocs (p ≤ .05, fold-change ≥ 2). (B) MGF genes that were not statistically signifi-
cantly overexpressed in any of the BM populations. They were expressed in MMC and at least one the environment subpopulation. See also legend 
of Figure 2.
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Table 2: Affymetrix expression of growth factor receptor genes in MMC.
MFG MGF receptor probeset Median (range) P (%)
on MMC on MMC
(n = 131) (n = 131)
- IGF-1 - IGF-1R 203627_at 19 (1-85) 32
- HGF - c-Met 203510_at 78 (4-728) 50
- CCL3 -CCR1 205098_at 136 (26-2840) 78
- GDF15 - not known --- --- ---
- PTN - RPTP-β/ζ/ 204469_at 24 (1-1958) 48
- BDNF - NTRK2 207152_at 84 (4-286) 77
IL-6 family
- IL-6 - IL-6R (gp80) 205945_at 502 (7-3657) 99
- IL6ST (gp130) 212195_at 1681 (210-5680) 100
- CNTF - CNTFR NA --- ---
- OSM - OSMR 205729_at 25 (1-88) 58
- LIF - LIFR 225575_at 16 (1-203) 15
- IL-11 - IL-11R 204773_at 61 (3-140) 26
- CLCF1 - CRLF1 206315_at 15 (2-91) 0
other interleukins
- IL-1β - IL-1R 202948_at 10 (1-63) 1
- IL-10 - IL-10RA 204912_at 212 (24-912) 92
- IL-10RB 209575_at 240 (98-536) 100
- IL-15 - IL-15R 207375_s_at 142 (16-403) 55
- IL-21 - IL-21R 221658_s_at 6 (1-395) 5
TNF family
- TNF-α - TNFRSF1A 241944_x_at 63 (4-233) 66
- BAFF - TNFRSF13B/TACI 207641_at 266 (50-745) 95
- APRIL - TNFRSF13C/Baff-R NA --- ---
- TNFRSF17/BCMA 206641_at 3794 (968-8301) 100
EGF family - ErbB1 211551_at 56 (6-148) 64
- ErbB2 216836_s_at 30 (2-106) 5
- ErbB3 202454_s_at 47 (79-172) 59
- ErbB4 214053_at 51 (2-1091) 38
VEGF family -VEGFR1/FLT1 NA --- ---
-VEGFR2/FLK1 NA --- ---
-VEGFR3/FLT4 NA --- ---Mahtouk et al. BMC Cancer 2010, 10:198
http://www.biomedcentral.com/1471-2407/10/198
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sion is increasing progressively throughout normal
plasma cell differentiation. 4 MGF and 9 MGF receptor
genes were overexpressed in "PPC+BMPC" compared to
B cells. 11 MGF and 11 MGF receptor genes were overex-
pressed in BMPC compared to PPC. This suggests that
PC differentiation, and in particular the transition from
immature plasmablast to mature plasma cell, is associ-
ated with a stronger dependence on growth factors. In
agreement with this finding, it has been shown that nor-
mal plasma cells can survive and produce antibodies for
v e r y  l o n g  p e r i o d s  a s  s o o n  a s  t h e y  a r e  l o c a t e d  i n  t h e
appropriate survival niches in the BM [25]. In contrast, 3
MGF genes only (AREG, NRG3 and Wnt5A) and none of
the MGF receptor genes were significantly overexpressed
in MMC compared to BMPC. One explanation is that
MMC use the same growth factors than normal plasma
cells. Accordingly, several growth factors for MMC also
support the survival of normal plasma cells, like IL-6,
BAFF and April [26,27], their specific receptors being
expressed both in normal and malignant plasma cells (see
table 2).
It was not in the scope of the study to validate the
Affymetrix expression of all MGF. However, some of
them have already been analysed by real-time RT-PCR
and described by our group, like members of the EGF-
family. Using real-time RT-PCR on MMC from 7 patients
and U133A+B Affymetrix microarrays on a different
cohort of 65 MM patients' samples, we have shown that
AREG [28], NRG2 and NRG3 [17] are significantly over-
expressed in MMC compared to their normal counter-
part. This is in agreement with the data presented here
(see Figure S-I). Previously, we also compared the expres-
sion of EGF-family members in MMC (n = 7 samples)
and in the total BM microenvironment (n = 7 samples),
using real-time RT-PCR. We have shown that NRG2 and
NRG3 are mainly expressed by MMC whereas HB-EGF is
mainly expressed by the environment [17]. Again, those
results correlate with the current Affymetrix data (see
figure 2 for NRG2 and NRG3; and figure 4A for HB-
EGF). Other examples of formerly validated genes are
Baff and April (Figures 4A and 3B), 2 members of the
TNF superfamilly that were already shown to be highly
FGF family - FGFR1 NA --- ---
- FGFR2 NA --- ---
- FGFR3 204379_s_at 4.2 (1-13160) 10
- FGFR4 NA --- ---
Wnt family - Frizzled1 (Frz1) 204451_at 75 (2-586) 34
- Frz2 210220_at 30 (1-680) 30
- Frz3 219683_at 80 (15-465) 19
- Frz4 218665_at 84 (2-348) 92
- Frz5 NA --- 8
- Frz6 203987_at 229 (6-1425)
- Frz7 203706_s_at 102 (12-2228) 98
- Frz8 227405_s_at 34 (3-338) 93
- Frz9 NA --- 15
- Frz10 NA --- ---
- LRP5 NA --- ---
- LRP6 225745_at 70 (1-137) 43
Jagged - Notch1 218902_at 85 (24-233) 47
- Notch2 212377_s_at 216 (43-1743) 100
- Notch3 203238_s_at 28 (1.4-95) 2
- Notch4 205247_at 40 (8-190) 35
MGF receptor genes expressed in more than 90% of the MMC samples are indicated in bold. MGF receptor genes expressed in less than 5% 
of the MMC samples are indicated in grey. Probe sets noted "NA" were considered to be not informative (see additional file 1).
Table 2: Affymetrix expression of growth factor receptor genes in MMC. (Continued)Mahtouk et al. BMC Cancer 2010, 10:198
http://www.biomedcentral.com/1471-2407/10/198
Page 14 of 18
expressed by the myeloma microenvironment compared
to the MMC themselves by real-time RT-PCR [9]. There-
fore, the good correlation between real-time RT-PCR
analysis performed in independent series of samples and
the Affymetrix expression profiles depicted here demon-
strates the relevance of the present study and shows the
power of microarrays to investigate as a whole the expres-
sion of MGF/MGFR genes in PC differentiation and MM.
Most interestingly, the microarrays analysis described
in this paper uncovers new MGF and MGFR and/or
describes for the fist time expression patterns of well
known MGF. The new and most striking findings are dis-
cussed in the following.
IL-6  is an essential growth factor for myeloma cells
[4,5]. Although it is now admitted that IL-6 is produced
by the environment, it has been reported that IL-6 is pro-
duced by MMC [4] and that autocrine IL-6 production
reflects a highly malignant phenotype [29]. Here we show
that BMSC are the main producer of IL-6, in agreement
with the literature data [30-32]. However, IL-6 can be
produced by MMC in some patients (36% presence, see
additional file 2, table S-II), but at a much lower extend
compared to BMSC (fold-chance in expression between
BMSC and MMC = 33.4). An important issue would be to
understand the significance of this low autocrine IL-6
expression, compared to the huge amounts produced by
BMSC. We have shown that a weak autocrine IL-6 pro-
duction is sufficient to trigger cell cycling on myeloma
cell lines (HMCL), whereas survival of those cells
requires large exogenous IL-6 concentrations [33]. It is
noteworthy that immature CD45+ MMC express the IL-6
gene, unlike mature MMC [34]. In this population, auto-
crine IL-6 could be sufficient to trigger cell cycling,
whereas the BM environment could be critical for trig-
gering survival by producing other survival factors. In
agreement with our previous findings [35], here we show
that IL-6R and gp130 are expressed in 99% and 100% of
the patients, respectively, indicating that the vast majority
of the patients, if not all, is able to respond to IL-6 stimu-
lation. We have recently shown that IL-6R expression in
MMC is a bad prognostic factor due to its strong associa-
tion with t(4:14) translocation [35]. Interestingly, both IL-
6R and gp130 were overexpressed in normal plasma cells
compared to B cells, in agreement with the known sur-
vival effect of IL-6 on plasma cells [26].
IGF-1 is an other essential growth factor for myeloma
cells [7,35,36] and inhibition of the IGF-1-pathway
reduces myeloma cell growth both in vitro and in vivo
[37-39]. It has been speculated that BMSC would be an
important source of IGF-1 in MM, probably based on the
fact that murine stromal cells do secrete IGF-1 [40].
However, we show here that MM-BMSC do not/weakly
express IGF-1. IGF-1 expression was 92-fold higher in
osteoclasts compared to BMSC (see Figures 3B) and 4/5
BMSC displayed an absent call for IGF-1 (additional file
2, table S-II). In addition, MMC from all 131 patients
expressed IGF-1. The presence of autocrine IGF-1 has
already been reported in some HMCL [7], but this is to
our knowledge the first study showing IGF-1 expression
as a hallmark of primary MMC. IGF-1R had 100% absent
call in BMPC whereas it was expressed in 32% of the
MMC samples (see table 2), suggesting that functional
IGF-1/IGF-1R autocrine loops are present in MMC of
those patients. Recently, we have shown that IGF-1R
expression in MMC delineates a group with adverse
prognosis [35].
HGF. Several evidences suggest that the HGF/c-Met
signalling pathway plays an important role in the biology
of MM [41-44]. Here we describe for the first time the
expression of c-Met in a large cohort of patients, and we
have found that it was expressed in MMC from 50% of
the patients. Although HGF expression in the environ-
ment (BMSC, CD14, PMN) was not statistically signifi-
cantly different than that in MMC, it should be noted that
HGF expression was very high in some patients' MMC
(range 1-5318) suggesting that autocrine HGF loops are
likely predominant in those high expresser patients. This
is in agreement with elevated HGF levels found in the
serum of some MM patients in association with advanced
stages of MM and extended bone lesions [45,46]. It is
noteworthy that HGF was overexpressed in MMC com-
pared to BMPC in the public data set from the group of
Shaughnessy (p ≤ .05, fold-change = 7.5, table S-VII). It
did not reach the significance in our data set, probably
because the number of samples is lesser.
Wnt-family. The expression of Wnt-family members
and FRZ receptors has been documented in some
myeloma cell lines [47] and in 4 primary MMC samples
[48], and the biological relevance of this pathway in MM
has been demonstrated [48,49]. In the present study, 8
Wnt were found in at least one BM subpopulation (MMC
and/or environment): Wnt 3, 4,10A, 11, 16, 5A, 5B, 6.
Noteworthy, Wnt5A was one of the 3 MGF significantly
overexpressed in MMC compared to normal BMPC. All 7
FRZ receptors that could be interrogated with Affymetrix
probe sets were expressed in some MMC samples and 3
of them (FRZ4, FRZ7, FRZ8) were expressed in more that
90% of the patients. LRP6, the required coreceptor of FRZ
receptors, was expressed in 43% of the MMC samples.
Altogether, those data indicate that Wnt/FRZ expression
is a hallmark of MM. Dikkopf-1, an inhibitor of Wnt sig-
naling expressed by primary MM cells, contributes to
osteolytic bone disease by inhibiting the differentiation
into osteoblasts [50]. Additional studies will be needed in
order to understand the impact of DKK1 on the W nt -
induced proliferation of myeloma cells. Furthermore, we
show that expression of several Wnt and FRZ is upregu-
lated during normal plasma cell differentiation. Wnt5AMahtouk et al. BMC Cancer 2010, 10:198
http://www.biomedcentral.com/1471-2407/10/198
Page 15 of 18
and Wnt10 as well as FRZ1,2,6,7,8 were overexpressed in
BMPC compared to PPC. FRZ1,3,6 were overexpressed
in (PPC+BMPC) compared to B cells. Those data provide
a rationale to investigate the role of the Wnt/FRZ family
in the biology of normal plasma cell.
FGF family. Analysis of the FGF/FGFR family in MM
has been mainly restricted to the angiogenic factor FGF2
(also called basic-FGF) and the nature of the cells produc-
ing FGF2 has remained controversial [32,51]. Here show
that BMSC are the main source of FGF2. FGF2 was also
expressed in 29% of the patients' MMC (38/131 present
call, median expression = 25) in agreement with the data
from Colla et al. [51], but the expression was 29.7-fold
lower than that in BMSC. Other BM subpopulations
(CD3, CD14, CD15) did not express FGF2 (see additional
file 2, table S-II and figure 3A), as previously reported by
Bisping et al. [32]. Furthermore, we show that other FGF-
family members are broadly expressed in MM. Among
the 13/22 FGFs that could be investigated with Affyme-
trix probe sets, 10 were expressed in at least one BM sub-
population (MMC and/or environment), suggesting that,
like FGF2, they may directly or indirectly stimulate MMC
survival and proliferation. Of note, it has been shown that
only FGF2, 8 and 13 could be detected at the protein level
on 12 HMCL whereas multiple FGFs were found at the
mRNA level [52]. Although it was not in the scope of our
study, FGF expression in MM should be validated at the
protein level.
Conclusion
In conclusion, this study provides an extensive descrip-
tion of MGF gene expression in the various cell popula-
tions of the BM of patients with MM, including MMC
and the environment, and during normal plasma cell dif-
ferentiation. We show an overexpression of MGF and
MGFR genes during plasma cell differentiation, in partic-
ular in BMPC compared to PPC. Additionally, this study
points out that the majority of MGF is expressed by the
tumor environment compared to MMC. Some MGF are
expressed by the MMC themselves, with a strong hetero-
geneity among patients. This study provides new insights
in the understanding of the intercellular communication
signals in MM, which is of major interest in order to
design efficient biologically-based treatments for MM.
List of abbreviations used
MM: multiple myeloma; MMC: myeloma cells; PPC:
polyclonal plasmablasts; BMPC: bone marrow plasma
cells; BM: bone marrow; BMSC: bone marrow stromal
cells; PMN: polymorphonuclear neutrophils; MGF:
myeloma growth factor; MGFR: myeloma growth factor
receptor.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KM designed research, performed the experiments, analyzed data and wrote
the paper. DH, TM, JFR and HG collected bone marrow samples and clinical
data. JM, DH, TR, MJ and STP analyzed data. BK is the senior investigator who
designed research and wrote the paper. All authors read and approved the
final manuscript.
Acknowledgements
This work was supported by grants from the Ligue Nationale Contre le Cancer 
(équipe labellisée, 2009), Paris, France, from INCA (n°R07001FN) and from 
BMSCNET European strep (N°E06005FF), the Hopp-Foundation, Germany, the 
University of Heidelberg, Germany, the National Centre for Tumor Diseases, 
Heidelberg, Germany, the Tumorzentrum Heidelberg/Mannheim, Germany.
Author Details
1INSERM, U847, Montpellier, F-34197 France, 2CHU Montpellier, Institute of 
Research in Biotherapy, F-34285 Montpellier, France, 3Medizinische Klinik V, 
Universitätsklinikum Heidelberg, INF410, D-69120 Heidelberg, Germany, 
4Nationales Centrum für Tumorerkrankungen, INF350, D-69120 Heidelberg, 
Germany, 5Université MONTPELLIER1, UFR Médecine, Montpellier, France and 
6Academic Medical Center, Department of Pathology, 1105 AZ Amsterdam, 
The Netherlands
References
1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, 
Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, 
Grosbois B, Bataille R: Single versus double autologous stem-cell 
transplantation for multiple myeloma.  N Engl J Med 2003, 
349(26):2495-2502.
2. Higgins MJ, Fonseca R: Genetics of multiple myeloma.  Best Pract Res Clin 
Haematol 2005, 18(4):525-536.
3. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, 
De Vos J, Rossi JF: Survival and proliferation factors of normal and 
malignant plasma cells.  Int J Hematol 2003, 78(2):106-113.
4. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoka H, Tang B, 
Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and 
essential requirement of BSF-2/IL-6 for human multiple myeloma.  
1988, 332:83-85.
5. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk 
M, Bataille R: Paracrine rather than autocrine regulation of myeloma-
cell growth and differentiation by interleukin-6.  Blood 1989, 
73(2):517-526.
Additional file 1 Gene expression profiling analysis. Material and 
methods describing how the so-called "non informative" probe sets were 
defined in the study.
Additional file 2 Expression of MGF genes in bone marrow cell popu-
lations and during normal plasma cell differentiation. The file includes 
7 tables showing the median expression and fold change in expression of 
MGF genes. Table S-I. Myeloma MGF genes. Table S-II. Myeloma niche MGF 
genes. Table S-III. Environment MGF genes. Table S-IV. Genes not statistically 
significantly overexpressed in cell populations. Table S-V. Expression of MGF 
during normal plasma cell differe. Table S-VI. Expression of MGF receptors 
during normal plasma cell differentiation and in MMC. Table S-VII. Expres-
sion of MGF and MGF receptors in BMPC and MMC samples from a public 
data set.
Additional file 3 Expression of MGF and MGF receptor genes during 
normal plasma cell differentiation and in MMC. The file includes 2 fig-
ures that summarize the MGF (Figure S-I) and MGF receptor (Figure S-II) 
gene expression during normal plasma cell differentiation and in MMC.
Received: 6 November 2009 Accepted: 13 May 2010 
Published: 13 May 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/198 © 2010 Mahtouk et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:198Mahtouk et al. BMC Cancer 2010, 10:198
http://www.biomedcentral.com/1471-2407/10/198
Page 16 of 18
6. Zhang XG, Bataille R, Widjenes J, Klein B: Interleukin-6 dependence of 
advanced malignant plasma cell dyscrasias.  1992, 69(6):1373-1376.
7. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K: Insulin-like 
growth factor I is a growth and survival factor in human multiple 
myeloma cell lines.  Blood 1996, 88:2250-2258.
8. De Vos J, Hose D, Reme T, Tarte K, Moreaux J, Mahtouk K, Jourdan M, 
Goldschmidt H, Rossi JF, Cremer FW, Klein B: Microarray-based 
understanding of normal and malignant plasma cells.  Immunol Rev 
2006, 210:86-104.
9. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, 
De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, 
Rossi JF, Hose D, Klein B: The level of TACI gene expression in myeloma 
cells is associated with a signature of microenvironment dependence 
versus a plasmablastic signature.  Blood 2005, 106(3):1021-1030.
10. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, Reme T, Legouffe E, 
Rossi JF, Shaughnessy J Jr, Orntoft TF, Klein B: Generation of polyclonal 
plasmablasts from peripheral blood B cells: a normal counterpart of 
malignant plasmablasts.  Blood 2002, 100(4):1113-1122.
11. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, Bret C, 
Duperray C, Hose D, Klein B: An in vitro model of differentiation of 
memory B cells into plasmablasts and plasma cells including detailed 
phenotypic and molecular characterization.  Blood 2009, 
114(25):5173-5181.
12. Reme T, Hose D, De Vos J, Vassal A, Poulain PO, Pantesco V, Goldschmidt 
H, Klein B: A new method for class prediction based on signed-rank 
algorithms applied to Affymetrix microarray experiments.  BMC 
Bioinformatics 2008, 9:16.
13. Assou S, Lecarrour T, Tondeur S, Strom S, Gabelle A, Marty S, Nadal L, 
Pantesco V, Reme T, Hugnot JP, Gasca S, Hovatta O, Hamamah S, Klein B, 
De Vos J: A meta-analysis of human embryonic stem cells 
transcriptome integrated into a web-based expression atlas.  Stem Cells 
2007.
14. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, 
Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, 
Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, 
Shaughnessy JD Jr: The molecular classification of multiple myeloma.  
Blood 2006, 108(6):2020-2028.
15. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, 
Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, 
Shaughnessy JD Jr: Gene-expression signature of benign monoclonal 
gammopathy evident in multiple myeloma is linked to good 
prognosis.  Blood 2007, 109(4):1692-1700.
16. Mahtouk K, Hose D, De Vos J, Moreaux J, Jourdan M, Rossi JF, Reme T, 
Goldschmidt H, Klein B: Input of DNA microarrays to identify novel 
mechanisms in multiple myeloma biology and therapeutic 
applications.  Clin Cancer Res 2007, 13(24):7289-7295.
17. Mahtouk K, Cremer FW, Reme T, Jourdan M, Baudard M, Moreaux J, 
Requirand G, Fiol G, De Vos J, Moos M, Quittet P, Goldschmidt H, Rossi JF, 
Hose D, Klein B: Heparan sulphate proteoglycans are essential for the 
myeloma cell growth activity of EGF-family ligands in multiple 
myeloma.  Oncogene 2006, 25(54):7180-7191.
18. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B: Interleukin-1 in 
multiple myeloma: producer cells and their role in the control of IL-6 
production.  Br J Haematol 1998, 103(4):1152-1160.
19. Gu ZJ, De Vos J, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, Wijdenes J, 
Klein B: Agonist anti-gp130 transducer monoclonal antibodies are 
human myeloma cell survival and growth factors.  Leukemia 2000, 
14(1):188-197.
20. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T: Cellular niches 
controlling B lymphocyte behavior within bone marrow during 
development.  Immunity 2004, 20(6):707-718.
21. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC: 
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 
pathways is required to induce apoptosis of multiple myeloma cells in 
the presence of bone marrow stromal cells.  Blood 2004, 
104(12):3712-3721.
22. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J: Myeloma 
interacts with the bone marrow microenvironment to induce 
osteoclastogenesis and is dependent on osteoclast activity.  Br J 
Haematol 2002, 116(2):278-290.
23. Cao W, Liu YJ: Innate immune functions of plasmacytoid dendritic cells.  
Curr Opin Immunol 2007, 19(1):24-30.
24. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, 
Danho C, Laharrague P, Klein B, Reme T, Bourin P: Bone marrow 
mesenchymal stem cells are abnormal in multiple myeloma.  Leukemia 
2007, 21(5):1079-1088.
25. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, 
Hiepe F: Competence and competition: the challenge of becoming a 
long-lived plasma cell.  Nat Rev Immunol 2006, 6(10):741-750.
26. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, 
Muehlinghaus G, Szyska M, Radbruch A, Manz RA: Plasma cell survival is 
mediated by synergistic effects of cytokines and adhesion-dependent 
signals.  J Immunol 2003, 171(4):1684-1690.
27. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin 
LL, Mantchev GT, Bram RJ, Noelle RJ: BCMA is essential for the survival of 
long-lived bone marrow plasma cells.  J Exp Med 2004, 199(1):91-98.
28. Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J, Fiol G, Raab 
M, Jourdan E, Grau V, Moos M, Goldschmidt H, Baudard M, Rossi JF, 
Cremer FW, Klein B: Expression of EGF-family receptors and 
amphiregulin in multiple myeloma. Amphiregulin is a growth factor for 
myeloma cells.  Oncogene 2005, 24(21):3512-3524.
29. Frassanito MA, Cusmai A, Iodice G, Dammacco F: Autocrine interleukin-6 
production and highly malignant multiple myeloma: relation with 
resistance to drug-induced apoptosis.  Blood 2001, 97(2):483-489.
30. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: 
Adhesion of human myeloma-derived cell lines to bone marrow 
stromal cells stimulates interleukin-6 secretion.  Blood 1993, 
82(12):3712-3720.
31. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, 
Berdel WE, Kienast J: Vascular endothelial growth factor and interleukin-
6 in paracrine tumor-stromal cell interactions in multiple myeloma.  
Blood 2000, 95(8):2630-2636.
32. Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Scheffold C, 
Kroger M, Mesters RM, Berdel WE, Kienast J: Paracrine interactions of 
basic fibroblast growth factor and interleukin-6 in multiple myeloma.  
Blood 2003, 101(7):2775-2783.
33. Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, Redal N, Duperray C, 
De Vos J, Klein B: Delineation of the roles of paracrine and autocrine 
interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A 
possible model for the cooperation of myeloma cell growth factors.  
Eur Cytokine Netw 2005, 16(1):57-64.
34. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 
gene expression in multiple myeloma: a characteristic of immature 
tumor cells.  1993, 81:3357-3364.
35. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, Barlogie B, 
Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, 
Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B: The 
role of IGF-1 as a major growth factor for myeloma cell lines and the 
prognostic relevance of the expression of its receptor.  Blood 2009.
36. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B: Insulin-like 
growth factor induces the survival and proliferation of myeloma cells 
through an IL-6-independent transduction pathway.  Br J Haematol 
2000, 111(2):626-634.
37. Menu E, Jernberg Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson 
O, Axelson M, Asosingh K, Nilsson K, Van Camp B, Vanderkerken K: 
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: 
an in vitro and in vivo study in the 5T33 MM mouse model.  Blood 2005.
38. Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, 
Lennartsson J, Hellman U, Carlson K, Osterborg A, Vanderkerken K, Nilsson 
K, Jernberg-Wiklund H: IGF-1 receptor tyrosine kinase inhibition by the 
cyclolignan PPP induces G2/M-phase accumulation and apoptosis in 
multiple myeloma cells.  Blood 2006, 107(2):669-678.
39. Descamps G, Wuilleme-Toumi S, Trichet V, Venot C, Debussche L, Hercend 
T, Collette M, Robillard N, Bataille R, Amiot M: CD45neg but not CD45pos 
human myeloma cells are sensitive to the inhibition of IGF-1 signaling 
by a murine anti-IGF-1R monoclonal antibody, mAVE1642.  J Immunol 
2006, 177(6):4218-4223.
40. Abboud SL, Bethel CR, Aron DC: Secretion of insulinlike growth factor I 
and insulinlike growth factor-binding proteins by murine bone 
marrow stromal cells.  J Clin Invest 1991, 88(2):470-475.Mahtouk et al. BMC Cancer 2010, 10:198
http://www.biomedcentral.com/1471-2407/10/198
Page 17 of 18
41. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A: Hepatocyte 
growth factor and its receptor c-met in multiple myeloma.  1996, 
88:3998-4004.
42. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST: 
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth 
factor binding and promotes Met signaling in multiple myeloma.  
Blood 2002, 99(4):1405-1410.
43. Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen 
JG, Waage A, Sundan A, Borset M: A selective c-met inhibitor blocks an 
autocrine hepatocyte growth factor growth loop in ANBL-6 cells and 
prevents migration and adhesion of myeloma cells.  Clin Cancer Res 
2004, 10(19):6686-6694.
44. Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, Otsuki 
T, Niikura T, Nukiwa T, Ikeda Y: NK4, an antagonist of hepatocyte growth 
factor (HGF), inhibits growth of multiple myeloma cells: molecular 
targeting of angiogenic growth factor.  Blood 2007, 109(7):3042-3049.
45. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A: Elevated 
serum concentrations of hepatocyte growth factor in patients with 
multiple myeloma. The Nordic Myeloma Study Group.  Blood 1998, 
91(3):806-812.
46. Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou 
DS: Elevated serum concentration of hepatocyte growth factor in 
patients with multiple myeloma: correlation with markers of disease 
activity.  Am J Hematol 2003, 72(4):229-233.
47. Qiang YW, Endo Y, Rubin JS, Rudikoff S: Wnt signaling in B-cell neoplasia.  
Oncogene 2003, 22(10):1536-1545.
48. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, 
Lokhorst HM, Bloem AC, Clevers H, Nusse R, Neut R van der, Spaargaren M, 
Pals ST: Illegitimate WNT signaling promotes proliferation of multiple 
myeloma cells.  Proc Natl Acad Sci USA 2004, 101(16):6122-6127.
49. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J 
Jr, Rudikoff S: Wnts induce migration and invasion of myeloma plasma 
cells.  Blood 2005, 106(5):1786-1793.
50. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr: 
The role of the Wnt-signaling antagonist DKK1 in the development of 
osteolytic lesions in multiple myeloma.  N Engl J Med 2003, 
349(26):2483-2494.
51. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P, Bonomini S, 
Hojden M, Martella E, Chisesi T, Rizzoli V, Giuliani N: Do human myeloma 
cells directly produce basic FGF?  Blood 2003, 102(8):3071-3072. author 
reply 3072-3073
52. Krejci P, Mekikian PB, Wilcox WR: The fibroblast growth factors in 
multiple myeloma.  Leukemia 2006, 20(6):1165-1168.
53. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY: Macrophage 
inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and 
signaling cascades mediating survival and proliferation in multiple 
myeloma (MM) cells.  Blood 2003, 101(9):3568-3573.
54. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD: 
Antisense inhibition of macrophage inflammatory protein 1-alpha 
blocks bone destruction in a model of myeloma bone disease.  J Clin 
Invest 2001, 108(12):1833-1841.
55. Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, 
Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR: Dual effects of 
macrophage inflammatory protein-1alpha on osteolysis and tumor 
burden in the murine 5TGM1 model of myeloma bone disease.  Blood 
2003, 102(1):311-319.
56. Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, 
Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda 
H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson 
KC: MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and 
inhibits the interaction of multiple myeloma cells and osteoclasts.  
Blood 2007, 110(10):3744-3752.
57. Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, 
Waterman G, Gordon MS, Ma J, Bonavida B, Berenson JR: Serum 
pleiotrophin levels are elevated in multiple myeloma patients and 
correlate with disease status.  Br J Haematol 2006, 133(5):526-529.
58. Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, 
Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida 
B, Berenson JR: Pleiotrophin is highly expressed by myeloma cells and 
promotes myeloma tumor growth.  Blood 2007, 110(1):287-295.
59. Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL: A neurotrophin 
axis in myeloma: TrkB and BDNF promote tumor-cell survival.  Blood 
2005, 105(11):4429-4436.
60. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, 
Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines 
as a model for tumor stem cell study in human multiple myeloma.  
Blood 1994, 83(12):3654-3663.
61. Jourdan M, De Vos J, Mechti N, Klein B: Regulation of Bcl-2-family 
proteins in myeloma cells by three myeloma survival factors: 
interleukin-6, interferon-alpha and insulin-like growth factor 1.  Cell 
Death Differ 2000, 7(12):1244-1252.
62. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin 6, a 
potent myeloma cell growth factor, as a reflect of disease severity in 
plasma cell dyscrasias.  JClinInvest 1989, 84(6):2008-2011.
63. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga 
T, Kishimoto T, Klein B: Increased and highly stable levels of functional 
soluble interleukin-6 receptor in sera of patients with monoclonal 
gammopathy.  Eur J Immunol 1993, 23(4):820-824.
64. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H: Interleukin-6 is a 
prognostic factor in multiple myeloma.  1991, 77:2794-2795.
65. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, 
Merlin M, Clement C, Morel-Fournier B: Murine anti-interleukin-6 
monoclonal antibody therapy for a patient with plasma cell leukemia.  
Blood 1991, 78(5):1198-1204.
66. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes 
J, Brochier J, Klein B: Biologic effects of anti-interleukin-6 murine 
monoclonal antibody in advanced multiple myeloma.  Blood 1995, 
86(2):685-691.
67. Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, Navarro 
R, Lopez E, Quittet P, Daures JP, Rouille V, Kanouni T, Widjenes J, Klein B: 
Optimizing the use of anti-interleukin-6 monoclonal antibody with 
dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: 
results of a pilot study including biological aspects.  Bone Marrow 
Transplant 2005, 36(9):771-779.
68. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, 
Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ: Inhibition of 
Interleukin-6 Signaling with CNTO 328 Enhances the Activity of 
Bortezomib in Preclinical Models of Multiple Myeloma.  Clin Cancer Res 
2007, 13(21):6469-6478.
69. Gu ZJ, Wijdenes J, Zhang XG, Hallet MM, Clement C, Klein B: Anti-gp130 
transducer monoclonal antibodies specifically inhibiting ciliary 
neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory 
factor or oncostatin M.  1996, 190(1):21-27.
70. Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, 
Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC: 
Functional significance of novel neurotrophin-1/B cell-stimulating 
factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth 
and survival.  Br J Haematol 2003, 123(5):869-878.
71. Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, 
Harousseau JL, Bataille R, Rossi JF, Klein B: Interleukin-10 is a proliferation 
factor but not a differentiation factor for human myeloma cells.  Blood 
1995, 85(9):2521-2527.
72. Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes 
J, Rossi JF, Klein B: Interleukin-10 is a growth factor for human myeloma 
cells by induction of an oncostatin M autocrine loop.  Blood 1996, 
88(10):3972-3986.
73. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R: Expression of functional 
interleukin-15 receptor and autocrine production of interleukin-15 as 
mechanisms of tumor propagation in multiple myeloma.  Blood 2000, 
95(2):610-618.
74. Brenne AT, Baade Ro T, Waage A, Sundan A, Borset M, Hjorth-Hansen H: 
Interleukin-21 is a growth and survival factor for human myeloma 
cells.  Blood 2002, 99(10):3756-3762.
75. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B: Tumor necrosis 
factor is a survival and proliferation factor for human myeloma cells.  
Eur Cytokine Netw 1999, 10(1):65-70.
76. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC: The 
role of tumor necrosis factor alpha in the pathophysiology of human 
multiple myeloma: therapeutic applications.  Oncogene 2001, 
20(33):4519-4527.Mahtouk et al. BMC Cancer 2010, 10:198
http://www.biomedcentral.com/1471-2407/10/198
Page 18 of 18
77. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I: The role of interleukin-1 
and tumour necrosis factor-alpha in human multiple myeloma.  Br J 
Haematol 1990, 74(4):424-431.
78. Borset M, Waage A, Brekke OL, Helseth E: TNF and IL-6 are potent growth 
factors for OH-2, a novel human myeloma cell line.  Eur J Haematol 1994, 
53(1):31-37.
79. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, 
Rossi JF, Klein B, Tarte K: BAFF and APRIL protect myeloma cells from 
apoptosis induced by interleukin 6 deprivation and dexamethasone.  
Blood 2004, 103(8):3148-3157.
80. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, 
Gross JA, Greipp PR, Jelinek DF: Expression of BCMA, TACI, and BAFF-R in 
multiple myeloma: a mechanism for growth and survival.  Blood 2004, 
103(2):689-694.
81. Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H, Matsumoto T: BAFF 
and APRIL as osteoclast-derived survival factors for myeloma cells: a 
rationale for TACI-Fc treatment in patients with multiple myeloma.  
Leukemia 2006, 20(7):1313-1315.
82. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr: 
Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma 
cells in SCID-hu mice and in coculture with osteoclasts.  Leukemia 2007.
83. Wang YD, De Vos J, Jourdan M, Couderc G, Lu ZY, Rossi JF, Klein B: 
Cooperation between heparin-binding EGF-like growth factor and 
interleukin-6 in promoting the growth of human myeloma cells.  
Oncogene 2002, 21(16):2584-2592.
84. Mahtouk K, Jourdan M, De Vos J, Hertogh C, Fiol G, Jourdan E, Rossi JF, 
Klein B: An inhibitor of the EGF receptor family blocks myeloma cell 
growth factor activity of HB-EGF and potentiates dexamethasone or 
anti-IL-6 antibody-induced apoptosis.  Blood 2004, 103(5):1829-1837.
85. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, 
Mathas S, Bargou RC, Manz R, Stein H, Dorken B: Jagged1-induced Notch 
signaling drives proliferation of multiple myeloma cells.  Blood 2004, 
103(9):3511-3515.
86. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, Nand S, Toor A, Alkan 
S, Smadja NV, Avet-Loiseau H, Lima CS, Miele L, Coignet LJ: 
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells 
from multiple myeloma patients and cell lines.  Blood 2004, 
104(12):3697-3704.
87. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI: Involvement of 
Notch-1 signaling in bone marrow stroma-mediated de novo drug 
resistance of myeloma and other malignant lymphoid cell lines.  Blood 
2004, 103(9):3503-3510.
88. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI: Inhibition 
of Notch signaling induces apoptosis of myeloma cells and enhances 
sensitivity to chemotherapy.  Blood 2007.
89. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta 
D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC: 
Vascular endothelial growth factor triggers signaling cascades 
mediating multiple myeloma cell growth and migration.  Blood 2001, 
98(2):428-435.
90. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, 
Rajkumar SV: Expression of VEGF and its receptors by myeloma cells.  
Leukemia 2003, 17(10):2025-2031.
91. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, Kumar 
S, Raje N, Richardson PG, Harousseau JL, Anderson KC: VEGF induces Mcl-
1 up-regulation and protects multiple myeloma cells against 
apoptosis.  Blood 2004, 104(9):2886-2892.
92. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, 
Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC: The small-
molecule VEGF receptor inhibitor pazopanib (GW786034B) targets 
both tumor and endothelial cells in multiple myeloma.  Proc Natl Acad 
Sci USA 2006, 103(51):19478-19483.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/198/prepub
doi: 10.1186/1471-2407-10-198
Cite this article as: Mahtouk et al., Growth factors in multiple myeloma: a 
comprehensive analysis of their expression in tumor cells and bone marrow 
environment using Affymetrix microarrays BMC Cancer 2010, 10:198